Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer Clinical Trial

Official title: Evaluation of the Efficacy and Safety of Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC): a Single-arm, Phase II Clinical Study

Status Recruiting

Clinical Trial Summary

Patients with advanced biliary tract malignant tumors who had not received systematic treatment before and could not be cured were selected as the subjects of the study. The primary endpoint of the study was investigator-assessed 6-month progression-free survival (6-month PFS%) based on the RECIST v1.1 criteria, and 43 subjects were planned to be enrolled. Patients eligible for enrollment will receive Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX).

Clinical Trial Description

This is an open-label, single-arm clinical study to observe and evaluate the efficacy and safety of Adebrelimab (PD-L1) and tyrosine kinase inhibitor (TKI) combined with gemcitabine and oxaliplatin (GEMOX) in the first-line treatment of patients with advanced biliary tract malignancies.

Subjects will be screened to receive Adebrelimab and TKI in combination with Gemcitabine and Oxaliplatin (GEMOX) after they are fully informed and sign the informed consent. Study treatment will continue until the subject develops intolerable toxicity, withdraws informed consent, and progresses as determined by the investigator in accordance with RECIST v1.1 (when the subject develops disease progression as defined in RECIST v1.1, if the investigator assesses that the subject continues to have clinical benefit and can tolerate the study treatment, The subject may continue treatment with the study drug; treatment may be terminated if the subject is no longer considered to have a clinical benefit), or other termination criteria specified in the protocol, whichever occurs first.

After the subjects were enrolled in the study, the safety visit will be conducted in D1 of each treatment cycle, and the safety visit and survival follow-up will be continued after the treatment.

Tumor imaging evaluation Imaging examination was performed every 6 weeks after enrollment to evaluate the efficacy. Additional imaging studies and evaluations may be performed at any time during the study if clinically indicated. Imaging evaluation of the tumor will continue until disease progression is confirmed by the investigator according to the RECIST v1.1 criteria or treatment is discontinued, whichever occurs later. Subjects who ended treatment for reasons other than investigator-confirmed disease progression (per RECIST v1.1) will also continue to be followed up at regular intervals for tumor imaging evaluation after the end of treatment.

If the subject withdraws the knowledge, has started other anti-tumor treatment (except Chinese patent medicine) or dies before the disease progression or termination of treatment confirmed by the investigator according to RECIST1.1 criteria, there is no need to continue the imaging evaluation. If the subject fails to meet the above termination criteria for imaging evaluation, the tumor efficacy evaluation of other efficacy evaluation criteria (RECIST v1.1, imRECIST) still needs to be continued even if the disease progression of a certain efficacy evaluation criteria occurs. ;

Related Conditions & MeSH terms

• Biliary Tract Cancer
• Biliary Tract Neoplasms
• Gemox Chemotherapy

• NCT number: NCT06320301
• Study type: Interventional
• Source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Contact: Wenbin Li, archiater
• Phone: 86-13602773101
• Email: gzsurgeon@163.com
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2024
• Completion date: June 1, 2026